{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Other
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
LM11A-31 is a small, nonpeptide, monomeric ligand of p75 neutrophin receptor (p75NTR). The compound promotes neuron survival in vitro. PharmatrophiX is developing a modified version of LM11A-31 (LM11A 31 BHS) for the oral treatment of Alzheimer's disease.
Status:
Other
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Status:
Other
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
3,5-Diiodo-L-thyronine (3,5-T2), a potential metabolite of 3,3',5-triiodothyronine (T3), is an active thyroid hormone. It acts as an alternative ligand for thyroid hormone receptor beta. 3,5-Diiodo-L-thyronine has the capacity to stimulate hepatic lipid catabolism but acts by different from T3 molecular mechanisms to achieve this effect.
![Structure of 6-(2-Fluorophenyl)-1,3-dioxolo[4,5-g]quinolin-8(5H)-one](/img/ac4ced98-0039-43aa-a1d4-c56549fe1523.svg?size=200&context=hkdzxotdtq)
![Structure of 2,3,3a,4,5,9b-Hexahydro-3-propyl-1H-benz[e]indol-8-ol, rel-(3aR,9bS)-](/img/e0714946-3867-44f4-8994-ac8b26491a7b.svg?size=200&context=hkdzxotdtq)
![Structure of [[[(3Z)-20-Oxopregn-4-en-3-ylidene]amino]oxy]acetic acid](/img/f9584f78-23e2-48b8-a88b-4dd04eae38c7.svg?size=200&context=hkdzxotdtq)
